Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Editorial
You have accessRestricted Access

Type 2 Diabetic Nephropathy: Never too Early to Treat?

Karl F. Hilgers and Roland Veelken
JASN March 2005, 16 (3) 574-575; DOI: https://doi.org/10.1681/ASN.2005010083
Karl F. Hilgers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland Veelken
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Type 2 diabetes mellitus is now the leading cause of end-stage renal disease in the United States and other developed countries (1). The pathogenesis of renal failure in type 2 diabetes is complex (1,2), but a role of the renin-angiotensin system (RAS) has been recognized for more than 15 years (3,4). In recent years, this notion has been confirmed by several large-scale clinical trials in patients with type 2 diabetes and renal disease (5). Blockers of the angiotensin II type 1 receptor (ARB) ameliorate the progression of overt nephropathy, independent from BP (6). Angiotensin-converting enzyme inhibitors (ACEI) as well as ARB decrease microalbuminuria and delay the progression from microalbuminuria to overt nephropathy (7,8). The recently published BENEDICT trial showed that ACEI retarded the development of new-onset microalbuminuria in hypertensive patients with type 2 diabetes, whereas a control antihypertensive drug did not (9). These trials supported a role of the RAS and marked a considerable step forward in the treatment of the disease. Nevertheless, several questions regarding the role of RAS blockade in type 2 diabetes remain to be answered. Are ARB superior to ACEI, or is a combination of both the most effective treatment? What are the optimal doses of ARB and ACEI? Can RAS blockade at best retard progression, or are these drugs able to reverse the loss of renal function as well? At what stage should RAS blockade be initiated? What is the role of nonhemodynamic mechanisms for the effects of RAS blockade?

This issue of the Journal of the American Society of Nephrology contains a report from an experimental study by Nagai and co-workers (10) which bears on several of these questions. The authors used Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of type 2 diabetes (11). These rats carry a defective cholecystokinine type A receptor gene, but the development of type 2 diabetes is nevertheless polygenic, not monogenic (12). OLETF rats also suffer from obesity, high BP, and hyperlipidemia (11), which may contribute to the development of renal damage. This complex pathogenesis of kidney injury could be viewed as a limitation of the model, but clinicians will instantly recognize the similarity to the metabolic syndrome in human type 2 diabetes (1). Furthermore, unlike most rodent models of diabetes, OLETF rats do develop nodular glomerular lesions (11).

Blockade of the RAS is known to ameliorate the progression of nephropathy in OLETF rats (13), but Nagai et al. (10) take the matter an important step further. The authors treated prediabetic rats from week 4 to week 11 of life with an ARB, an ACEI, a combination of both drugs, or hydralazine for comparison. At this age, blood glucose, body weight, and BP did not yet differ between OLETF rats and the respective nondiabetic, lean control animals. Treatment was then stopped, and the rats were followed for another 39 wk. The most striking observation was that transient RAS blockade in young rats had a lasting beneficial effect on glomerular structure and proteinuria despite the fact that the treated rats developed obesity, hypertension, and hyperglycaemia to an extent similar to that of untreated OLETF rats (10). This effect of RAS blockade was evident regardless of whether ACEI, ARB, or a combination of both drugs was used but was absent in the hydralazine group. It was important that the RAS was inhibited at all; the choice of ACEI, ARB, or combination was secondary, at least in this model. The doses of the drugs were not precisely monitored but appeared to be in the moderate to high dose range for rodents.

How can such a striking, long-term, renoprotective effect of a transient RAS blockade be explained? The first reports on the benefits of RAS antagonists in diabetic nephropathy focused on the correction of glomerular hypertension and hyperfiltration (14). Such a mechanism, however, is rather unlikely to account for structural benefits observed 39 wk after cessation of RAS blockade (10). Moreover, the increase of glomerular size in OLETF rats was not affected by RAS blockade (10), indicating that hyperfiltration was present. In contrast, the results provide some evidence that nonhemodynamic, profibrotic effects of angiotensin II may account for the findings (15). The gene expression of connective tissue growth factor, and of collagens I and IV, was elevated in young OLETF rats and was almost normalized by RAS blockade. This effect was sustained until 50 wk of age (10). The lack of data on matrix metalloproteases and collagen deposition limits the impact of these results. However, the findings suggest that transient RAS blockade at a young age can ameliorate the programming of a profibrotic phenotype. The phenomenon should not be confused with the deleterious impairment of kidney development induced by RAS blockade at an much younger age, i.e., during the neonatal period (16). At least in rats, the optimal age to induce lasting renoprotection by transient RAS blockade appears to be adolescence and/or very early adulthood (4 to 10 wk of age), based on the data of Nagai et al. (10) and the reports of others on the prevention of hypertensive nephrosclerosis (17). The molecular mechanisms of “reprogramming” at this age are not fully understood and will require further study.

Blockade of the RAS could help alleviate the metabolic syndrome and delay the onset of type 2 diabetes. This phenomenon has been increasingly recognized in clinical studies during recent years (18). Nagai et al. (10) argue against such an explanation for their findings, but others have previously reported that RAS blockade leads to metabolic improvements also in OLETF rats (19). One has to be careful in extrapolating from data obtained in animal models. However, the results by Nagai et al. (10) support the notion that treatment with RAS blockers should be started early, before diabetes becomes obvious, in subjects at risk for developing type 2 diabetes. Whether such early treatment could possibly obviate the need for later, more intense treatment in humans remains to be investigated. Moreover, the findings underscore the pivotal role of a stimulation of the intrarenal RAS in the pathogenesis of diabetic nephropathy. The development of tests to evaluate the activity of the intrarenal RAS in humans could help identify the patients who will benefit most from early RAS blockade.

 See related article, “Temporary Angiotensin II Blockade at the Prediabetic State Attenuates the Development of Renal Injury in Type 2 Diabetes Rats,” on pages 703–711.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • © 2005 American Society of Nephrology

References

  1. ↵
    Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341 : 1127 –1133, 1999
    OpenUrlCrossRefPubMed
  2. ↵
    Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352 : 213 –219, 1998
    OpenUrlCrossRefPubMed
  3. ↵
    Anderson S, Brenner BM: Pathogenesis of diabetic glomerulopathy: Hemodynamic considerations. Diabetes Metab Rev 4 : 163 –177, 1988
    OpenUrlPubMed
  4. ↵
    Ritz E, Hasslacher C, Mann J: Rational drug treatment of the hypertensive diabetic with nephropathy. J Diabet Complications 2 : 171 –174, 1988
    OpenUrlPubMed
  5. ↵
    Hilgers KF, Mann JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 13 : 1100 –1108, 2002
    OpenUrlFREE Full Text
  6. ↵
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 : 851 –860, 2001
    OpenUrlCrossRefPubMed
  7. ↵
    HOPE Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355 :2 53 –259, 2000
    OpenUrlCrossRefPubMed
  8. ↵
    Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 : 870 –878, 2001
    OpenUrlCrossRefPubMed
  9. ↵
    Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 : 1941 –1951, 2004
    OpenUrlCrossRefPubMed
  10. ↵
    Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A: Temporary Angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 16 : 703 –711, 2005
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T: Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41 : 1422 –1428, 1992
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Nara Y, Gao M, Ikeda K, Sato T, Sawamura M, Kawano K, Yamori Y: Genetic analysis of non-insulin-dependent diabetes mellitus in the Otsuka Long-Evans Tokushima Fatty rat. Biochem Biophys Res Commun 241 : 200 –204, 1997
    OpenUrlCrossRefPubMed
  13. ↵
    Kim S, Wanibuchi H, Hamaguchi A, Miura K, Yamanaka S, Iwao H: Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension 30 : 1054 –1061, 1997
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77 : 1925 –1930, 1986
  15. ↵
    Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29 : 153 –163, 1997
    OpenUrlCrossRefPubMed
  16. ↵
    Hilgers KF, Norwood VF, Gomez RA: Angiotensin’s role in renal development. Semin Nephrol 17 : 492 –501, 1997
    OpenUrlPubMed
  17. ↵
    Nakaya H, Sasamura H, Hayashi M, Saruta T: Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 12 : 659 –666, 2001
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Messerli FH, Grossman E, Leonetti G: Antihypertensive therapy and new onset diabetes. J Hypertens 22 : 1845 –1847, 2004
    OpenUrlCrossRefPubMed
  19. ↵
    Uehara Y, Hirawa N, Numabe A, Kawabata Y, Nagoshi H, Negoro H, Fujiwara S, Gomi T, Ikeda T, Goto A, Omata M: Angiotensin-converting enzyme inhibition delays onset of glucosuria with regression of renal injuries in genetic rat model of non-insulin-dependent diabetes mellitus. J Cardiovasc Pharmacol Ther 3 : 327 –336, 1998
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 16 (3)
Journal of the American Society of Nephrology
Vol. 16, Issue 3
1 Mar 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Type 2 Diabetic Nephropathy: Never too Early to Treat?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Type 2 Diabetic Nephropathy: Never too Early to Treat?
Karl F. Hilgers, Roland Veelken
JASN Mar 2005, 16 (3) 574-575; DOI: 10.1681/ASN.2005010083

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Type 2 Diabetic Nephropathy: Never too Early to Treat?
Karl F. Hilgers, Roland Veelken
JASN Mar 2005, 16 (3) 574-575; DOI: 10.1681/ASN.2005010083
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Can Diet Induce Transplantation Tolerance?
  • Counterpoint: Twice-Weekly Hemodialysis Should Be an Approach of Last Resort Even in Times of Dialysis Unit Stress
  • Mitochondria Matter: A Critical Role of ADCK4 in Stabilizing the CoQ Complex in Podocytes in Steroid-Resistant Nephrotic Syndrome
Show more Editorial

Cited By...

  • Effects of Adrenomedullin on Cardiac Oxidative Stress and Collagen Accumulation in Aldosterone-Dependent Malignant Hypertensive Rats
  • Is the Kidney Always the Cause of Hypertension?: Distinct Roles for the Kidney and Systemic Tissues in Blood Pressure Regulation by the Renin-Angiotensin System. J Clin Invest 115: 1092-1099, 2005
  • Google Scholar

Similar Articles

Related Articles

  • Temporary Angiotensin II Blockade at the Prediabetic Stage Attenuates the Development of Renal Injury in Type 2 Diabetic Rats
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire